A project for science

Our entrepreneurial approach is a responsible one and we have made a long-term commitment to science by pledging to donate part of our profits to biomedical research.

A project for science

Our entrepreneurial approach is a responsible one and we have made a long-term commitment to science by pledging to donate part of our profits to biomedical research.


A project
for science

Our entrepreneurial approach is a responsible one and we have made a long-term commitment to science by pledging to donate part of our profits to biomedical research.

Image

Professor emeritus, world leading specialist in tissue regeneration.

With both of his parents doctors, Professor Denis Barritault was drawn to molecular biology at a young age. He joined the CNRS at 22 where he wrote his PhD thesis. After having taken a post-PhD course in molecular immunology in New York, he returned to France to focus his research on tissue ageing. He submitted his first patent application in 1979 after he discovered the effect of growth factors on skin lesion repair. Appointed Professor to the Paris Est Créteil University in 1982, he created the CRRET, a laboratory to become a worldwide research reference centre on tissue regeneration, affiliated to the CNRS in 1994.

In 1990, further to his avant-garde work on growth factors, he invented a technology based on reinforced heparan sulphate biomimetics, which proved to be a new regenerative medicine therapeutic class. RGNA28, our exclusive anti-ageing active ingredient was derived from this biotechnology. This discovery paved the way to matrix therapy, a revolutionary new treatment method consisting of treating the environment surrounding cells to restore the regeneration message, rather than the cells themselves.

Denis Barritault is currently Professor Emeritus at Paris-EST University, and honorary director of the CRRET laboratory. He is considered one of the world’s leading specialists in tissue repair and regeneration. He has co-written more than 200 publications and is credited as inventor in more than thirty patents.

Image

Professor emeritus, world leading specialist in tissue regeneration.

With both of his parents doctors, Professor Denis Barritault was drawn to molecular biology at a young age. He joined the CNRS at 22 where he wrote his PhD thesis. After having taken a post-PhD course in molecular immunology in New York, he returned to France to focus his research on tissue ageing. He submitted his first patent application in 1979 after he discovered the effect of growth factors on skin lesion repair. Appointed Professor to the Paris Est Créteil University in 1982, he created the CRRET, a laboratory to become a worldwide research reference centre on tissue regeneration, affiliated to the CNRS in 1994.


Image

Image

Image

In 1990, further to his avant-garde work on growth factors, he invented a technology based on reinforced heparan sulphate biomimetics, which proved to be a new regenerative medicine therapeutic class. RGNA28, our exclusive anti-ageing active ingredient was derived from this biotechnology. This discovery paved the way to matrix therapy, a revolutionary new treatment method consisting of treating the environment surrounding cells to restore the regeneration message, rather than the cells themselves.

Denis Barritault is currently Professor Emeritus at Paris-EST University, and honorary director of the CRRET laboratory. He is considered one of the world’s leading specialists in tissue repair and regeneration. He has co-written more than 200 publications and is credited as inventor in more than thirty patents.

Image

Laboratory OTR3 : French biomedical research specialist

After winning the French national competition for the creation of innovative companies-Concours National de Création d’Entreprise Innovante, Professor Barritault co-founded the biotechnology laboratory OTR3, a tissue regeneration centre of expertise in 2000. The objective of OTR3 is to continue to develop the heparan sulphate biomimetics technology, in order to develop new indications and innovative health products.

OTR3 is currently marketing two medical devices used in hospitals to promote tissue regeneration in complex and/or chronic cases of wound healing, or for the regeneration of corneal wounds caused by ulcers and surgery.

Ongoing developments

This biotechnological discovery is full of promise for conditions for which there are no effective treatment to date. For instance, the development aiming to reduce post-stroke conditions was selected from among over a hundred innovative projects, and received funding from the European Commission in 2018. In a similar way, a development project on neuronal protection for Alzheimer’s cases was awarded a prize from the French Agence Nationale de Recherche.

Image

Laboratory OTR3 : French biomedical research specialist

After winning the French national competition for the creation of innovative companies-Concours National de Création d’Entreprise Innovante, Professor Barritault co-founded the biotechnology laboratory OTR3, a tissue regeneration centre of expertise in 2000. The objective of OTR3 is to continue to develop the heparan sulphate biomimetics technology, in order to develop new indications and innovative health products.

OTR3 is currently marketing two medical devices used in hospitals to promote tissue regeneration in complex and/or chronic cases of wound healing, or for the regeneration of corneal wounds caused by ulcers and surgery.

Ongoing developments

This biotechnological discovery is full of promise for conditions for which there are no effective treatment to date. For instance, the development aiming to reduce post-stroke conditions was selected from among over a hundred innovative projects, and received funding from the European Commission in 2018. In a similar way, a development project on neuronal protection for Alzheimer’s cases was awarded a prize from the French Agence Nationale de Recherche.

Image

Laboratory OTR3 : French biomedical research specialist

After winning the French national competition for the creation of innovative companies-Concours National de Création d’Entreprise Innovante, Professor Barritault co-founded the biotechnology laboratory OTR3, a tissue regeneration centre of expertise in 2000. The objective of OTR3 is to continue to develop the heparan sulphate biomimetics technology, in order to develop new indications and innovative health products.

OTR3 is currently marketing two medical devices used in hospitals to promote tissue regeneration in complex and/or chronic cases of wound healing, or for the regeneration of corneal wounds caused by ulcers and surgery.

 
Image
Image
Image

Ongoing developments

This biotechnological discovery is full of promise for conditions for which there are no effective treatment to date. For instance, the development aiming to reduce post-stroke conditions was selected from among over a hundred innovative projects, and received funding from the European Commission in 2018. In a similar way, a development project on neuronal protection for Alzheimer’s cases was awarded a prize from the French Agence Nationale de Recherche.

Image

A responsible project, for science

We have embarked on a responsible trade approach.

Corporate responsibility: we commit to science by donating part of our profits to biomedical research, in order to contribute to its development and global reach.

Ethical responsibility: we commit to go beyond applicable legislation in our formulations, in application of the principle of precaution to the highest degree in the selection of our ingredients and our preservatives.

Natural responsibility: we commit to formulate our care range with at least 90% natural ingredients, without impacting the efficacy of our products.

Image

A responsible project, for science

We have embarked on a responsible trade approach.

Corporate responsibility: we commit to science by donating part of our profits to biomedical research, in order to contribute to its development and global reach.

Ethical responsibility: we commit to go beyond applicable legislation in our formulations, in application of the principle of precaution to the highest degree in the selection of our ingredients and our preservatives.

Natural responsibility: we commit to formulate our care range with at least 90% natural ingredients, without impacting the efficacy of our products.

Image
 
Image
Image
 

Ecological responsibility: we commit to minimise the environmental impact in terms of ingredient procurement and packaging production. We ensure we used recyclable or recycled materials from sustainable sources. We also produce exclusively in Europe in order to minimise our carbon footprint as far as possible.

Innovative responsibility: we commit to only market products that are genuinely innovative and effective through our exclusive, patented active ingredient RGNA28..

 

Ecological responsibility: we commit to minimise the environmental impact in terms of ingredient procurement and packaging production. We ensure we used recyclable or recycled materials from sustainable sources. We also produce exclusively in Europe in order to minimise our carbon footprint as far as possible.

Innovative responsibility: we commit to only market products that are genuinely innovative and effective through our exclusive, patented active ingredient RGNA28..